A CROSS SECTIONAL STUDY TO ASSESS VARIOUS FACTORS AFFECTING TREATMENT OUTCOME OF SHORTER MULTI DRUG RESISTANT TUBERCULOSIS REGIMEN AT A TERTIARY HEALTH

Abstract

Background: - A significant burden is multidrug or rifampicin resistant tuberculosis
(MDR/RR-TB).
Poses a global danger to the prevention and eradication of TB worldwide. Since 2016, WHO
recommendations have allowed for the option of treating MDR/RR-TB with a conventional
regimen lasting 9 to 11 months (referred to as the "shorter regimen") as opposed to a
customized regimen lasting at least 20 months. The goal of the current study was to pinpoint
variables influencing how well MDR-TB patients responded to a shorter injectable-based
regimen.